Liraglutide did not improve LV ejection fraction (mean difference 0%; 95% CI -3 to 2) or diastolic function (E/A difference -0.09; 95% CI -0.23 to 0.05) in South Asian type 2 diabetes patients.
RCT (n=47)
Double-blind
randomized
Does liraglutide improve LV diastolic and systolic function in South Asian type 2 diabetes patients?
Liraglutide treatment for 26 weeks did not improve LV diastolic or systolic function, aortic stiffness, or myocardial tissue characteristics in South Asian patients with type 2 diabetes.
Mean Difference: 0 (95% CI -3–2)
BACKGROUND: The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide may be beneficial in the regression of diabetic cardiomyopathy. South Asian ethnic groups in particular are at risk of developing type 2 diabetes. PURPOSE: To assess the effects of liraglutide on left ventricular (LV) diastolic and systolic function in South Asian type 2 diabetes patients. STUDY TYPE: Prospective, double-blind, randomized, placebo-controlled trial. POPULATION: Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo. FIELD STRENGTH/SEQUENCE: mapping). ASSESSMENT: Primary endpoints were changes in LV diastolic function (early deceleration peak Edec, ratio of early and late peak filling rate E/A, estimated LV filling pressure E/Ea) and LV systolic function (ejection fraction). Secondary endpoints were changes in aortic stiffness (aortic pulse wave velocity PWV), myocardial steatosis (myocardial triglyceride content), and diffuse fibrosis (extracellular volume ECV). STATISTICAL TESTS: Data were analyzed according to intention-to-treat. Between-group differences were reported as mean (95% confidence interval CI) and were assessed using analysis of covariance (ANCOVA). RESULTS: (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)). Aortic PWV (+0.5 m/s (-0.6;1.6)), myocardial triglyceride content (+0.21% (-0.09;0.51)), and ECV (-0.2% (-1.4;1.0)) were unaltered. DATA CONCLUSION: Liraglutide did not affect LV diastolic and systolic function, aortic stiffness, myocardial triglyceride content, or extracellular volume in Dutch South Asian type 2 diabetes patients with or without coronary artery disease. LEVEL OF EVIDENCE: 1 Technical Efficacy Stage: 4 J. Magn. Reson. Imaging 2020;51:1679-1688.
Paiman et al. (Wed,) conducted a rct in Type 2 diabetes (n=47). Liraglutide vs. Placebo was evaluated on Changes in LV diastolic function (Edec, E/A, E/Ea) and LV systolic function (ejection fraction) (MD 0%, 95% CI -3 to 2). Liraglutide did not improve LV ejection fraction (mean difference 0%; 95% CI -3 to 2) or diastolic function (E/A difference -0.09; 95% CI -0.23 to 0.05) in South Asian type 2 diabetes patients.